Donna Thomas, BSN, RN, OCN

Articles

Oncology Drug Crash Course: Fam-Trastuzumab Deruxtecan-Nxki (Enhertu)

November 08, 2022

After demonstrating significant efficacy as a third-line treatment for patients with metastatic HER2-positive breast cancer, fam-trastuzumab deruxtecan-nxki has gained approval from the FDA for 4 indications and is under investigation across solid tumors.